First Tracks Biotherapeutics (TRAX) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vor Biopharma is the larger company by market cap ($1.11 billion vs $1.09 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRAX | VOR |
|---|---|---|
| Share price | $30.59 | $18.78 |
| Market cap | $1.09B | $1.11B |
| 1-day change | -2.55% | +2.57% |
| YTD return | — | +43.58% |
| 1-year return | — | -44.44% |
| 5-year return | — | -93.93% |
| P/E ratio (TTM) | — | 0.10 |
| EPS (TTM) | $-4.71 | $184.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $49.91 | $33.50 |
| 52-week low | $14.72 | $6.50 |
| Distance from 52-week high | -38.71% | -43.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +128.83% | +107.67% |
| Average volume | 792.69K | 999.37K |
| Shares outstanding | 35.73M | 59.16M |
| Employees | 104 | 76 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About First Tracks Biotherapeutics
TRAX stock →First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.
Healthcare · Biotechnology · 104 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Healthcare · Biotechnology · 76 employees
TRAX vs VOR FAQ
Which is bigger, First Tracks Biotherapeutics or Vor Biopharma?
Vor Biopharma (VOR) is larger, with a market capitalization of $1.11B compared with $1.09B for First Tracks Biotherapeutics (TRAX).
Are First Tracks Biotherapeutics and Vor Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.